|
1
|
Gewirtz DA: A critical evaluation of the
mechanisms of action proposed for the antitumor effects of the
anthracycline antibiotics adriamycin and daunorubicin. Biochem
Pharmacol. 57:727–741. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Minotti G, Menna P, Salvatorelli E, Cairo
G and Gianni L: Anthracyclines: Molecular advances and
pharmacologic developments in antitumor activity and
cardiotoxicity. Pharmacol Rev. 56:185–229. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
McGowan JV, Chung R, Maulik A, Piotrowska
I, Walker JM and Yellon DM: Anthracycline chemotherapy and
cardiotoxicity. Cardiovasc Drugs Ther. 31:63–75. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Nooter K, Sonneveld P, Oostrum R,
Herweijer H, Hagenbeek T and Valerio D: Overexpression of the mdr1
gene in blast cells from patients with acute myelocytic leukemia is
associated with decreased anthracycline accumulation that can be
restored by cyclosporin-A. Int J Cancer. 45:263–268. 1990.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Berman E and McBride M: Comparative
cellular pharmacology of daunorubicin and idarubicin in human
multidrug-resistant leukemia cells. Blood. 79:3267–3273. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhou XW, Xia YZ, Zhang YL, Luo JG, Han C,
Zhang H, Zhang C, Yang L and Kong LY: Tomentodione M sensitizes
multidrug resistant cancer cells by decreasing P-glycoprotein via
inhibition of p38 MAPK signaling. Oncotarget. 8:101965–101983.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Mankhetkorn S, Dubru F, Hesschenbrouck J,
Fiallo M and Garnier-Suillerot A: Relation among the resistance
factor, kinetics of uptake, and kinetics of the
P-glycoprotein-mediated efflux of doxorubicin, daunorubicin,
8-(S)-fluoroidarubicin, and idarubicin in multidrug-resistant K562
cells. Mol Pharmacol. 49:532–539. 1996.PubMed/NCBI
|
|
8
|
Roovers DJ, van Vliet M, Bloem AC and
Lokhorst HM: Idarubicin overcomes P-glycoprotein-related multidrug
resistance: Comparison with doxorubicin and daunorubicin in human
multiple myeloma cell lines. Leuk Res. 23:539–548. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Vander Heiden MG, Cantley LC and Thompson
CB: Understanding the Warburg effect: The metabolic requirements of
cell proliferation. Science. 324:1029–1033. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Orang AV, Petersen J, McKinnon RA and
Michael MZ: Micromanaging aerobic respiration and glycolysis in
cancer cells. Mol Metab. 23:98–126. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gu L, Yi Z, Zhang Y, Ma Z, Zhu Y and Gao
J: Low dose of 2-deoxy-D-glucose kills acute lymphoblastic leukemia
cells and reverses glucocorticoid resistance via N-linked
glycosylation inhibition under normoxia. Oncotarget. 8:30978–30991.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Pelicano H, Martin DS, Xu RH and Huang P:
Glycolysis inhibition for anticancer treatment. Oncogene.
25:4633–4646. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Garg AD, Maes H, van Vliet AR and
Agostinis P: Targeting the hallmarks of cancer with therapy-induced
endoplasmic reticulum (ER) stress. Mol Cell Oncol. 2:e9750892014.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
DeSalvo J, Kuznetsov JN, Du J, Leclerc GM,
Leclerc GJ, Lampidis TJ and Barredo JC: Inhibition of Akt
potentiates 2-DG-induced apoptosis via downregulation of UPR in
acute lymphoblastic leukemia. Mol Cancer Res. 10:969–978. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Badiner GJ, Moy BC, Smith KS, Tarpley WG,
Groppi VE and Bhuyan BK: P388 leukaemia cells resistant to the
anthracycline menogaril lack multidrug resistant phenotype. Br J
Cancer. 62:378–384. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kiue A, Sano T, Naito A, Inada H, Suzuki
K, Okumura M, Kikuchi J, Sato S, Takano H, Kohno K, et al: Reversal
by two dihydropyridine compounds of resistance to multiple
anticancer agents in mouse P388 leukemia in vivo and in vitro. Jpn
J Cancer Res. 81:1057–1064. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Aboudkhil S, Henry L, Zaid A and Bureau
JP: Effect of testosterone on growth of P388 leukemia cell line in
vivo and in vitro. Distribution of peripheral blood T lymphocytes
and cell cycle progression. Neoplasma. 52:260–266. 2005.PubMed/NCBI
|
|
18
|
Matsuo T and Sadzuka Y: Extracellular
acidification by lactic acid suppresses glucose deprivation-induced
cell death and autophagy in B16 melanoma cells. Biochem Biophys Res
Commun. 496:1357–1361. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Song K, Li M, Xu X, Xuan LI, Huang G and
Liu Q: Resistance to chemotherapy is associated with altered
glucose metabolism in acute myeloid leukemia. Oncol Lett.
12:334–342. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Staubert C, Bhuiyan H, Lindahl A, Broom
OJ, Zhu Y, Islam S, Linnarsson S, Lehtiö J and Nordström A: Rewired
metabolism in drug-resistant leukemia cells: A metabolic switch
hallmarked by reduced dependence on exogenous glutamine. J Biol
Chem. 290:8348–8359. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Miwa H, Shikami M, Goto M, Mizuno S,
Takahashi M, Tsunekawa-Imai N, Ishikawa T, Mizutani M, Horio T,
Gotou M, et al: Leukemia cells demonstrate a different metabolic
perturbation provoked by 2-deoxyglucose. Oncol Rep. 29:2053–2057.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Raez LE, Papadopoulos K, Ricart AD,
Chiorean EG, Dipaola RS, Stein MN, Rocha Lima CM, Schlesselman JJ,
Tolba K, Langmuir VK, et al: A phase I dose-escalation trial of
2-deoxy-D-glucose alone or combined with docetaxel in patients with
advanced solid tumors. Cancer Chemother Pharmacol. 71:523–530.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Stein M, Lin H, Jeyamohan C, Dvorzhinski
D, Gounder M, Bray K, Eddy S, Goodin S, White E and Dipaola RS:
Targeting tumor metabolism with 2-deoxyglucose in patients with
castrate-resistant prostate cancer and advanced malignancies.
Prostate. 70:1388–1394. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Maximchik P, Abdrakhmanov A, Inozemtseva
E, Tyurin-Kuzmin PA, Zhivotovsky B and Gogvadze V:
2-Deoxy-D-glucose has distinct and cell line-specific effects on
the survival of different cancer cells upon antitumor drug
treatment. FEBS J. 285:4590–4601. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Reyes R, Wani NA, Ghoshal K, Jacob ST and
Motiwala T: Sorafenib and 2-deoxyglucose synergistically inhibit
proliferation of both sorafenib-sensitive and -resistant HCC cells
by inhibiting ATP production. Gene Expr. 17:129–140. 2017.
View Article : Google Scholar : PubMed/NCBI
|
